- List
- By Topic
- On Map
- Search Details

gantenerumab (12 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03236844 | Completed | Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
114 | All | 18 Years to 80 Years (Adult, Senior) | NCT03236844 | WP40052 | August 1, 2017 | December 15, 2017 | December 15, 2017 | August 2, 2017 | January 17, 2018 |
|
||
2 | NCT03443973 | Not yet recruiting | Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
760 | All | 50 Years to 90 Years (Adult, Senior) | NCT03443973 | WN39658 2017-001365-24 |
July 31, 2018 | July 1, 2022 | June 20, 2023 | February 23, 2018 | April 18, 2018 |
|
||
3 | NCT03444870 | Not yet recruiting | Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
760 | All | 50 Years to 90 Years (Adult, Senior) | NCT03444870 | WN29922 2017-001364-38 |
July 31, 2018 | July 1, 2022 | June 20, 2023 | February 23, 2018 | April 18, 2018 |
|
||
4 | NCT02882009 | Completed | A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
48 | All | 40 Years to 80 Years (Adult, Senior) | NCT02882009 | WP39322 | August 31, 2016 | March 22, 2017 | March 22, 2017 | August 29, 2016 | June 20, 2017 |
|
||
5 | NCT02711423 | Completed | A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
18 | Male | 18 Years to 45 Years (Adult) | NCT02711423 | BP30042 2015-005132-17 |
March 31, 2016 | September 28, 2016 | September 28, 2016 | March 17, 2016 | April 10, 2018 |
|
||
6 | NCT02133937 | Completed | A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
31 | All | 40 Years to 70 Years (Adult, Senior) | NCT02133937 | BP29113 | April 2014 | September 2014 | September 2014 | May 8, 2014 | November 2, 2016 |
|
||
7 | NCT02051608 | Active, not recruiting | A Study of Gantenerumab in Participants With Mild Alzheimer Disease |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
389 | All | 50 Years to 90 Years (Adult, Senior) | NCT02051608 | WN28745 2013-003390-95 |
March 27, 2014 | April 13, 2018 | November 20, 2020 | January 31, 2014 | March 27, 2018 |
|
||
8 | NCT01656525 | Completed | A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
28 | All | 50 Years to 80 Years (Adult, Senior) | NCT01656525 | JP22431 JapicCTI-121849 |
June 2012 | March 2014 | June 2014 | August 3, 2012 | September 19, 2014 |
|
||
9 | NCT01224106 | Active, not recruiting | A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
799 | All | 50 Years to 85 Years (Adult, Senior) | NCT01224106 | WN25203 2010-019895-66 |
November 30, 2010 | April 13, 2018 | November 20, 2020 | October 19, 2010 | March 27, 2018 |
|
||
10 | NCT01636531 | Completed | A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
120 | All | 40 Years to 70 Years (Adult, Senior) | NCT01636531 | WP27951 2011-006093-65 |
May 2012 | October 2012 | October 2012 | July 10, 2012 | November 2, 2016 |
|
||
11 | NCT00531804 | Completed | A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease. |
|
|
Interventional | Phase 1 |
|
Industry |
|
|
60 | All | 50 Years to 90 Years (Adult, Senior) | NCT00531804 | NN19866 | December 2006 | September 2010 | September 2010 | September 19, 2007 | November 2, 2016 |
|
||
12 | NCT01760005 | Recruiting | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. |
|
|
Interventional | Phase 2 Phase 3 |
|
Other / Industry / NIH |
|
|
438 | All | 18 Years to 80 Years (Adult, Senior) | NCT01760005 | DIAN-TU-001 The Alzheimer's Association U01AG042791 2013-000307-17 R01AG046179 REec-2014-0817 R56AG053267 GHR Foundation |
DIAN-TU | December 2012 | September 2023 | December 2023 | January 3, 2013 | January 23, 2018 |
|
† Study has passed its completion date and status has not been verified in more than two years.